Snapshot · Huberman Lab
Neuroplasticity triggered by grief processing is consolidated during deep sleep and non-sleep deep rest (NSDR) — 10 to 30-minute behavioral protocols shown to accelerate neural rewiring.
Where this was said
At 37:00 · chapter starts 34:59
The closing section ties the entire episode together into an actionable framework. Rational grieving, as Huberman defines it, is the deliberate practice of holding two things simultaneously: a clear-eyed acceptance that the person no longer exists in the same space-time dimensionality, and an undiminished anchoring to the depth of the attachment that existed. [1] — Andrew Huberman "Grief processing triggers neuroplasticity — but the actual neural rewiring happens during deep sleep and non-sleep deep rest (NSDR) protoco…" 34:50 This is not a passive emotional state — it is cognitive effort, and it triggers neuroplasticity. But the rewiring itself — the literal reorganization of the attachment map — occurs during deep sleep and non-sleep deep rest (NSDR) protocols of 10 to 30 minutes. Without adequate sleep, the grief work done during waking hours cannot consolidate. Huberman closes with a broader reflection that resonates emotionally: the depth of our attachments, and the richness of shared experience, is precisely what makes life meaningful. The grief those attachments eventually cause is not a reason to hold back — it is evidence of a life fully lived. He invites listeners to lean into building connections, trusting that the tools discussed today offer a path through whatever losses those connections will one day bring.
Animals first sensed light 540 million years ago, triggering an evolutionary acceleration known as the Cambrian explosion within 10 million years.
It is estimated that half of all cortical activity in the human brain is involved in visual function, underscoring vision's central role in intelligence.
Cognitive neuroscience literature shows that by age 6, humans can recognize tens of thousands of different object categories — far more data than early AI systems were trained on.
Only about 3% of FDA-approved drugs have genuinely unclear mechanisms of action, making an unknown mechanism a meaningful early red flag for any compound.
Even compounds that clear preclinical testing often fail in humans: 30 to 50% of drugs entering phase 1 trials do not advance to phase 2, frequently because human behavior differs from animal models.
More than 80% of published BPC-157 research comes from a single academic group whose researchers have IP and commercial interests connected to the molecule, limiting independent replication.
Roughly 100 peptide drugs are already FDA-approved, about 150 more are in clinical trials, and 600–700 are in preclinical development, underscoring the legitimacy of peptide science broadly.
The scientist who discovered BPC-157 refused to disclose the screening method used to identify the compound and has never fully published the parent protein sequence — what Peter Attia calls 'scientific trust me, bro.'
The brain's visual, auditory, and motor cortices light up nearly identically whether an experience is real or imagined, making visualization a form of actual neural training.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.